Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01307631 · ClinicalTrials.gov registry record · Phase 2
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
A Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 7
- Study locations
NCT01307631: Completed Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, sponsored by National Cancer Institute (NCI).
NCT01307631 is a Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 37 participants, below the 337-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (89% lower). The trial reports 7 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01307631, a Phase 2 study of Endometrial Adenocarcinoma and Endometrial Serous Adenocarcinoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 7
- Study locations
Study Summary
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with recurrent or advanced endometrial cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Primary Outcome
Activity will be ascertained by the proportion of patients who survive progression-free for at least 6 months after initiating therapy or who have objective tumor response. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions. Any pathological lymph node must have reduction in short axis to \< 10 mm; Partial Response (PR), at least 30% decrease in the sum of the longest diameter
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Akt Inhibitor MK2206
Study Locations (7)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber Cancer Institute - Boston
- Beth Israel Deaconess Medical Center - Boston
- Massachusetts General Hospital - Charlestown
- Newton-Wellesley Hospital - Newton
New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2011-03 |
| Est. Completion | 2015-09-18 |
| Phase | Phase 2 |
What the finished NCT01307631 record still lists
NCT01307631 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 337-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (89% lower).
The record links to 5 conditions, with Endometrial Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01307631 lists 7 locations in 3 states (Massachusetts, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT01307631 about?
NCT01307631 is a clinical study titled "Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer". This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with recurrent or advanced endometrial cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01307631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2011-03. Estimated completion is 2015-09-18.
What conditions does trial NCT01307631 study?
This clinical trial studies the following conditions: Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Endometrial Adenosquamous Carcinoma.
What interventions are being tested in trial NCT01307631?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Akt Inhibitor MK2206 (DRUG).
Who is sponsoring clinical trial NCT01307631?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01307631 being conducted?
This trial has 7 study locations across Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01307631's enrollment target sits among peer trials
37 9th of 13 higher than 4 of 13 other Endometrial Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RECRUITING · Phase 2
-
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RECRUITING · Phase 2
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
-
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
ACTIVE NOT RECRUITING · Phase 2
-
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia